Ramipril
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glomerulonephritis
Conditions
Glomerulonephritis
Trial Timeline
Jul 1, 2004 → Sep 1, 2010
NCT ID
NCT00437463About Ramipril
Ramipril is a phase 3 stage product being developed by Sanofi for Glomerulonephritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00437463. Target conditions include Glomerulonephritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00437463 | Phase 3 | Completed |
| NCT00273533 | Phase 2/3 | Completed |
| NCT00268619 | Phase 3 | Completed |
| NCT01053910 | Approved | Completed |
| NCT00325806 | Approved | Completed |
Competing Products
8 competing products in Glomerulonephritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil | Daiichi Sankyo | Phase 2 | 52 |
| infusion of ADR-001 (Mesenchymal stem cell) | Rohto Pharmaceutical | Phase 1 | 33 |
| Iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Roche | Phase 2/3 | 65 |
| ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin | Pfizer | Phase 2 | 51 |
| MOR202 | Biogen | Phase 1/2 | 38 |
| MOR202 | Biogen | Phase 2 | 49 |